Aerovate Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

Jade Biosciences

11/08/2023 14:20

* Aerovate Therapeutics Inc  AVTE.OQ   AVTE.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 14 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Aerovate
Therapeutics Inc
is for a loss of 70 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aerovate
Therapeutics Inc is $27​, above​ its last closing price
of $15.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.61       -0.60      -0.67     Missed  -11.7
 Dec. 31 2023  -0.71       -0.62      -0.61     Beat    1.3
 Sep. 30 2022  -0.50       -0.50      -0.56     Missed  -12.4​
 Jun. 30 2022  -0.46       -0.45      -0.49     Missed  -7.8
 ​​Mar.        -0.34       -0.28      -0.45     Missed  -62.2
 31 2022                                                
 Dec. 31 2021  -0.26       -0.31      -0.35     Missed  -13.8​
 Sep. 30 2021  -0.26       -0.26      -0.26     Met     0
 Jun. 30 2021  -0.16       -0.16      -23.80    Missed  -15,09
                                                        1.2
 This summary was machine generated August 11 at 13:20 GMT.  All
figures in US dollars  unless otherwise stated